Decellularized hASCs-derived matrices as biomaterials for 3D in vitro approaches.
Maia FR., Reis RL., Oliveira JM.
Laboratory Study, published in Methods Cell Biol (2020) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Methods Cell Biol (2020)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 32222226
- DOI
- 10.1016/bs.mcb.2019.11.019
- Citations
- 10
Abstract (original English)
Tissue regeneration strategies have been greatly evolving in the last years due to the use of more realistic approaches. These approaches rely in the use of biomaterials for the development of three dimensional (3D) structures that emulate the in vivo microenvironment of different tissues. Recently, extracellular matrices (ECM) secreted by cells have been caught a great deal of attention as an attractive biomaterial for the development 3D structures. In fact, different cells and/or different cellular culture conditions gave rise to different ECM's compositions, which can be used for the development of more physiologically relevant 3D structures. Nevertheless, the recovery of cell-derived ECM requires the use of a proper decellularization protocol. Herein, we report a decellularization protocol to recover the ECM produced by human adipose derived stem cells. This protocol comprises multiple steps (chemical, physical or enzymatic) which are described here in more detail. Furthermore, it is describe the methods that have been used to evaluate the effectiveness of this decellularization protocol. Overall, this protocol enables the production of hASCs-derived matrices that can be further used for the production of more physiologically relevant 3D in vitro models for tissue regeneration strategies.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.